{"transactions":[{"id":4616592,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:09.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026."}],"balance_after":803699,"source":{"system":"sec-edgar","filing":"0001193125-26-389892","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897618/000119312526389892/ownership.xml","form_type":"4"}},{"id":4616593,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:08.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":362133,"source":{"system":"sec-edgar","filing":"0001193125-26-389890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526389890/ownership.xml","form_type":"4"}},{"id":4616594,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:06.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 208 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026."}],"balance_after":508279,"source":{"system":"sec-edgar","filing":"0001193125-26-389889","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526389889/ownership.xml","form_type":"4"}},{"id":4616595,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24154,"kind":"person","name":"Roberts Brandi","position":1,"cik":"0001516354","reported_name":"Roberts Brandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:05.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 918 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026."}],"balance_after":397905,"source":{"system":"sec-edgar","filing":"0001193125-26-389888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526389888/ownership.xml","form_type":"4"}},{"id":4616596,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:03.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":2244640,"source":{"system":"sec-edgar","filing":"0001193125-26-389887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897557/000119312526389887/ownership.xml","form_type":"4"}},{"id":5104,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-09-05T01:30:03.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":19023,"price":37.94,"value":721732.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1494640,"source":{"system":"sec-edgar","filing":"0001193125-26-384042","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1897557/000119312526384042/ownership.xml","form_type":"4"}},{"id":5103,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-09-05T01:30:03.000Z","date":"2026-09-02","kind":"grant","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective February 3, 2026.  Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026."}],"balance_after":1513663,"source":{"system":"sec-edgar","filing":"0001193125-26-384042","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897557/000119312526384042/ownership.xml","form_type":"4"}},{"id":689333,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:10.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":1473246,"source":{"system":"sec-edgar","filing":"0001193125-26-345839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345839/ownership.xml","form_type":"4"}},{"id":689332,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:08.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":603282,"source":{"system":"sec-edgar","filing":"0001193125-26-345838","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345838/ownership.xml","form_type":"4"}},{"id":689331,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:06.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":383071,"source":{"system":"sec-edgar","filing":"0001193125-26-345837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345837/ownership.xml","form_type":"4"}},{"id":689330,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:05.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":237133,"source":{"system":"sec-edgar","filing":"0001193125-26-345836","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345836/ownership.xml","form_type":"4"}},{"id":689329,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24154,"kind":"person","name":"Roberts Brandi","position":1,"cik":"0001516354","reported_name":"Roberts Brandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:03.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":271987,"source":{"system":"sec-edgar","filing":"0001193125-26-345835","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345835/ownership.xml","form_type":"4"}},{"id":725574,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:10.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":13008,"price":45.03,"value":585750.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."}],"balance_after":320571,"source":{"system":"sec-edgar","filing":"0001193125-26-285567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285567/ownership.xml","form_type":"4"}},{"id":725564,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24154,"kind":"person","name":"Roberts Brandi","position":1,"cik":"0001516354","reported_name":"Roberts Brandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:07.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":3013,"price":45.03,"value":135675.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 30, 2025."}],"balance_after":209487,"source":{"system":"sec-edgar","filing":"0001193125-26-285563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285563/ownership.xml","form_type":"4"}},{"id":725563,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:05.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":29208,"price":45.03,"value":1315236.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."}],"balance_after":1098246,"source":{"system":"sec-edgar","filing":"0001193125-26-285562","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285562/ownership.xml","form_type":"4"}},{"id":725562,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:04.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":10035,"price":45.03,"value":451876.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."}],"balance_after":503282,"source":{"system":"sec-edgar","filing":"0001193125-26-285564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285564/ownership.xml","form_type":"4"}},{"id":725561,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:03.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":2867,"price":45.03,"value":129101.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2025."}],"balance_after":174633,"source":{"system":"sec-edgar","filing":"0001193125-26-285558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285558/ownership.xml","form_type":"4"}},{"id":730577,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:06.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance\nshare unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":177500,"source":{"system":"sec-edgar","filing":"0001193125-26-276881","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276881/ownership.xml","form_type":"4"}},{"id":730573,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:05.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":1127454,"source":{"system":"sec-edgar","filing":"0001193125-26-276882","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276882/ownership.xml","form_type":"4"}},{"id":730572,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24154,"kind":"person","name":"Roberts Brandi","position":1,"cik":"0001516354","reported_name":"Roberts Brandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:04.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance\nshare unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":212500,"source":{"system":"sec-edgar","filing":"0001193125-26-276880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276880/ownership.xml","form_type":"4"}},{"id":730571,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:04.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance\nshare unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":333579,"source":{"system":"sec-edgar","filing":"0001193125-26-276879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276879/ownership.xml","form_type":"4"}},{"id":730570,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:03.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance\nshare unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":513317,"source":{"system":"sec-edgar","filing":"0001193125-26-276878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276878/ownership.xml","form_type":"4"}},{"id":737895,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:22.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271164/ownership.xml","form_type":"4"}},{"id":737894,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:22.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":24289,"source":{"system":"sec-edgar","filing":"0001193125-26-271164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271164/ownership.xml","form_type":"4"}},{"id":737893,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:21.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271163","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271163/ownership.xml","form_type":"4"}},{"id":737892,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:21.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19900,"source":{"system":"sec-edgar","filing":"0001193125-26-271163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271163/ownership.xml","form_type":"4"}},{"id":737891,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:17.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271160","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271160/ownership.xml","form_type":"4"}},{"id":737890,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:17.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":21210,"source":{"system":"sec-edgar","filing":"0001193125-26-271160","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271160/ownership.xml","form_type":"4"}},{"id":737889,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38197,"kind":"person","name":"Krebs Andreas","position":1,"cik":"0001438946","reported_name":"Krebs Andreas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:14.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271157","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271157/ownership.xml","form_type":"4"}},{"id":737888,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38197,"kind":"person","name":"Krebs Andreas","position":1,"cik":"0001438946","reported_name":"Krebs Andreas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:14.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19773,"source":{"system":"sec-edgar","filing":"0001193125-26-271157","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271157/ownership.xml","form_type":"4"}},{"id":737887,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24269,"kind":"person","name":"Adsett Roger","position":1,"cik":"0001685904","reported_name":"Adsett Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":14620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":14620,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":14620},"source":{"system":"sec-edgar","filing":"0001193125-26-271155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271155/ownership.xml","form_type":"4"}},{"id":737886,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24269,"kind":"person","name":"Adsett Roger","position":1,"cik":"0001685904","reported_name":"Adsett Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":3555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":3555,"source":{"system":"sec-edgar","filing":"0001193125-26-271155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271155/ownership.xml","form_type":"4"}},{"id":737885,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:04.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271154/ownership.xml","form_type":"4"}},{"id":737884,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:04.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":24289,"source":{"system":"sec-edgar","filing":"0001193125-26-271154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271154/ownership.xml","form_type":"4"}},{"id":827418,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-03-26T22:43:44.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":8018,"price":18.47,"value":148092.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of\nthe Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan."}],"balance_after":413317,"source":{"system":"sec-edgar","filing":"0001193125-26-126830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526126830/ownership.xml","form_type":"4"}},{"id":827417,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-26T22:42:48.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":10702,"price":18.47,"value":197665.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of\nthe Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount includes 793 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan."}],"balance_after":271079,"source":{"system":"sec-edgar","filing":"0001193125-26-126827","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526126827/ownership.xml","form_type":"4"}},{"id":827416,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-03-26T22:42:23.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":24431,"price":18.47,"value":451240.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan."}],"balance_after":752454,"source":{"system":"sec-edgar","filing":"0001193125-26-126825","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526126825/ownership.xml","form_type":"4"}},{"id":917826,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2026-02-05T22:00:10.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":115000,"source":{"system":"sec-edgar","filing":"0001193125-26-039598","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039598/ownership.xml","form_type":"4"}},{"id":917825,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24154,"kind":"person","name":"Roberts Brandi","position":1,"cik":"0001516354","reported_name":"Roberts Brandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-02-05T21:57:19.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001193125-26-039585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039585/ownership.xml","form_type":"4"}},{"id":917824,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-02-05T21:55:45.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":407576,"source":{"system":"sec-edgar","filing":"0001193125-26-039579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039579/ownership.xml","form_type":"4"}},{"id":917823,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-02-05T21:54:52.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":575025,"source":{"system":"sec-edgar","filing":"0001193125-26-039576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039576/ownership.xml","form_type":"4"}},{"id":917822,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2026-02-05T21:53:18.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":1098477,"source":{"system":"sec-edgar","filing":"0001193125-26-039571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039571/ownership.xml","form_type":"4"}},{"id":927938,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24269,"kind":"person","name":"Adsett Roger","position":1,"cik":"0001685904","reported_name":"Adsett Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-30T01:35:22.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable over a three-year period with 1/3 vesting on the first anniversary of the date of the grant and the remaining vesting in 24 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":17.24,"expiration_date":"2036-01-28","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-029915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526029915/ownership.xml","form_type":"4"}},{"id":958270,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-12-29T22:00:08.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":5600,"price":13.1469,"value":73622.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":425025,"source":{"system":"sec-edgar","filing":"0001193125-25-335484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525335484/ownership.xml","form_type":"4"}},{"id":958268,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-12-29T22:00:06.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":25791,"price":13.1469,"value":339071.6979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":778477,"source":{"system":"sec-edgar","filing":"0001193125-25-335483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525335483/ownership.xml","form_type":"4"}},{"id":958269,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-12-29T22:00:03.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":11276,"price":13.1469,"value":148244.4444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":282576,"source":{"system":"sec-edgar","filing":"0001193125-25-335481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525335481/ownership.xml","form_type":"4"}},{"id":1031772,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-09-26T21:35:36.000Z","date":"2025-09-25","kind":"sale","planned":true,"acquired":false,"shares":11278,"price":9.77,"value":110186.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."}],"balance_after":293852,"source":{"system":"sec-edgar","filing":"0001193125-25-220848","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525220848/ownership.xml","form_type":"4"}},{"id":1031771,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-09-26T21:35:13.000Z","date":"2025-09-25","kind":"sale","planned":true,"acquired":false,"shares":25797,"price":9.77,"value":252036.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."}],"balance_after":804268,"source":{"system":"sec-edgar","filing":"0001193125-25-220847","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525220847/ownership.xml","form_type":"4"}},{"id":1031770,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-09-26T21:34:29.000Z","date":"2025-09-25","kind":"sale","planned":true,"acquired":false,"shares":7704,"price":9.77,"value":75268.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."}],"balance_after":430625,"source":{"system":"sec-edgar","filing":"0001193125-25-220843","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525220843/ownership.xml","form_type":"4"}},{"id":1101109,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-06-26T20:30:09.000Z","date":"2025-06-25","kind":"sale","planned":true,"acquired":false,"shares":11491,"price":6.8,"value":78138.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":305130,"source":{"system":"sec-edgar","filing":"0000950170-25-090431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025090431/ownership.xml","form_type":"4"}},{"id":1101106,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-06-26T20:30:05.000Z","date":"2025-06-25","kind":"sale","planned":true,"acquired":false,"shares":7848,"price":6.8,"value":53366.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":438329,"source":{"system":"sec-edgar","filing":"0000950170-25-090429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025090429/ownership.xml","form_type":"4"}},{"id":1101105,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-06-26T20:30:04.000Z","date":"2025-06-25","kind":"sale","planned":true,"acquired":false,"shares":26491,"price":6.8,"value":180138.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":830065,"source":{"system":"sec-edgar","filing":"0000950170-25-090428","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025090428/ownership.xml","form_type":"4"}},{"id":1109864,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38197,"kind":"person","name":"Krebs Andreas","position":1,"cik":"0001438946","reported_name":"Krebs Andreas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:09.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086767","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086767/ownership.xml","form_type":"4"}},{"id":1109863,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:08.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086766","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086766/ownership.xml","form_type":"4"}},{"id":1109862,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086765","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086765/ownership.xml","form_type":"4"}},{"id":1109861,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:05.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086764/ownership.xml","form_type":"4"}},{"id":1109860,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:04.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086763","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086763/ownership.xml","form_type":"4"}},{"id":1127778,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24154,"kind":"person","name":"Roberts Brandi","position":1,"cik":"0001516354","reported_name":"Roberts Brandi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T21:40:03.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":7.26,"expiration_date":"2035-06-01","underlying":"Common Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-25-080407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025080407/ownership.xml","form_type":"4"}},{"id":1191013,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-03-26T21:00:18.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":21208,"price":6.74,"value":142941.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":856556,"source":{"system":"sec-edgar","filing":"0000950170-25-045397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025045397/ownership.xml","form_type":"4"}},{"id":1191012,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-03-26T21:00:17.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":6836,"price":6.74,"value":46074.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":446177,"source":{"system":"sec-edgar","filing":"0000950170-25-045396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025045396/ownership.xml","form_type":"4"}},{"id":1191011,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-03-26T21:00:13.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":6576,"price":6.74,"value":44322.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":316621,"source":{"system":"sec-edgar","filing":"0000950170-25-045394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025045394/ownership.xml","form_type":"4"}},{"id":1191009,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":81525,"kind":"person","name":"Liao Carrie","position":1,"cik":"0001899817","reported_name":"Liao Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-03-26T21:00:10.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":2347,"price":6.74,"value":15818.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":144923,"source":{"system":"sec-edgar","filing":"0000950170-25-045393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025045393/ownership.xml","form_type":"4"}},{"id":1200166,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24155,"kind":"person","name":"Wiley Matthew T.","position":1,"cik":"0001759703","reported_name":"Wiley Matthew T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-18T20:45:05.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date"}],"balance_after":350000,"derivative":{"exercise_price":6.35,"expiration_date":"2035-03-16","underlying":"Common Shares","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000950170-25-041302","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025041302/ownership.xml","form_type":"4"}},{"id":1207875,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2025-03-13T20:30:13.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 1,098 shares acquired under the Mind Medicine (MindMed) Inc. 2024 Employee Share Purchase Plan on February 18, 2025."}],"balance_after":877764,"source":{"system":"sec-edgar","filing":"0000950170-25-038801","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025038801/ownership.xml","form_type":"4"}},{"id":1207874,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2025-03-13T20:30:11.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":453013,"source":{"system":"sec-edgar","filing":"0000950170-25-038800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025038800/ownership.xml","form_type":"4"}},{"id":1207873,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-03-13T20:30:09.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":323197,"source":{"system":"sec-edgar","filing":"0000950170-25-038798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025038798/ownership.xml","form_type":"4"}},{"id":1207872,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":81525,"kind":"person","name":"Liao Carrie","position":1,"cik":"0001899817","reported_name":"Liao Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2025-03-13T20:30:07.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":142270,"source":{"system":"sec-edgar","filing":"0000950170-25-038796","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025038796/ownership.xml","form_type":"4"}},{"id":1321007,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-12-27T21:31:46.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":19106,"price":7.43,"value":141957.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":526666,"source":{"system":"sec-edgar","filing":"0001104659-24-132167","document":"tm2432133-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465924132167/tm2432133-4_4seq1.xml","form_type":"4"}},{"id":1321006,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":81525,"kind":"person","name":"Liao Carrie","position":1,"cik":"0001899817","reported_name":"Liao Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2024-12-27T21:31:15.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":2273,"price":7.43,"value":16888.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66 The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":97270,"source":{"system":"sec-edgar","filing":"0001104659-24-132166","document":"tm2432133-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465924132166/tm2432133-3_4seq1.xml","form_type":"4"}},{"id":1321005,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2024-12-27T21:30:42.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":6643,"price":7.43,"value":49357.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":338013,"source":{"system":"sec-edgar","filing":"0001104659-24-132164","document":"tm2432133-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465924132164/tm2432133-2_4seq1.xml","form_type":"4"}},{"id":1321004,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-12-27T21:30:16.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":4519,"price":7.43,"value":33576.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":173197,"source":{"system":"sec-edgar","filing":"0001104659-24-132160","document":"tm2432133-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465924132160/tm2432133-1_4seq1.xml","form_type":"4"}},{"id":1341700,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-12-05T21:30:05.000Z","date":"2024-12-05","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":7.17,"value":17925.0,"ownership":{"direct":true},"balance_after":19851,"source":{"system":"sec-edgar","filing":"0000950170-24-133724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024133724/ownership.xml","form_type":"4"}},{"id":1399512,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":81525,"kind":"person","name":"Liao Carrie","position":1,"cik":"0001899817","reported_name":"Liao Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2024-09-26T00:30:17.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":2352,"price":5.98,"value":14064.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":99543,"source":{"system":"sec-edgar","filing":"0000950170-24-109450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024109450/ownership.xml","form_type":"4"}},{"id":1399511,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-09-26T00:29:51.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":19771,"price":5.98,"value":118230.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":545772,"source":{"system":"sec-edgar","filing":"0000950170-24-109449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024109449/ownership.xml","form_type":"4"}},{"id":1399510,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2024-09-26T00:29:15.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":6871,"price":5.98,"value":41088.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":344656,"source":{"system":"sec-edgar","filing":"0000950170-24-109448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024109448/ownership.xml","form_type":"4"}},{"id":1399509,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-09-26T00:28:35.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":4430,"price":5.98,"value":26491.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":177716,"source":{"system":"sec-edgar","filing":"0000950170-24-109447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024109447/ownership.xml","form_type":"4"}},{"id":1423334,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-08-26T23:00:03.000Z","date":"2024-08-23","kind":"purchase","planned":false,"acquired":true,"shares":3500,"price":5.98,"value":20930.0,"ownership":{"direct":true},"balance_after":17351,"source":{"system":"sec-edgar","filing":"0000950170-24-100668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024100668/ownership.xml","form_type":"4"}},{"id":1425418,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":88070,"kind":"person","name":"Halperin Wernli Miri","position":1,"cik":"0001897615","reported_name":"Halperin Wernli Miri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-22T20:30:13.000Z","date":"2024-08-21","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the option to purchase 50,000 common shares of the Issuer, which vested over a period of four years following the date of the grant of February 27, 2020. All such options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2025-02-27","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-099872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099872/ownership.xml","form_type":"4"}},{"id":1425417,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":88070,"kind":"person","name":"Halperin Wernli Miri","position":1,"cik":"0001897615","reported_name":"Halperin Wernli Miri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive President"}}],"security":"Common Shares","published_at":"2024-08-22T20:30:13.000Z","date":"2024-08-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":32595,"price":6.17,"value":201111.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Transaction represents a \"net exercise\" of an outstanding stock option to purchase an aggregate of 50,000 common shares of the Issuer granted on February 27, 2020. The Reporting Person received 17,405 common shares of the Issuer on the net exercise of the stock option. The Issuer withheld 32,595 common shares underlying the stock option for payment of the exercise price and tax withholding using a stock price of $6.17, which represents the closing price of the Issuer's common shares on August 20, 2024, the day before the exercise."}],"balance_after":202405,"source":{"system":"sec-edgar","filing":"0000950170-24-099872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099872/ownership.xml","form_type":"4"}},{"id":1425416,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":88070,"kind":"person","name":"Halperin Wernli Miri","position":1,"cik":"0001897615","reported_name":"Halperin Wernli Miri","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive President"}}],"security":"Common Shares","published_at":"2024-08-22T20:30:13.000Z","date":"2024-08-21","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":3.7,"value":185000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of Reporting Person's stock option that would otherwise expire February 27, 2025."}],"balance_after":235000,"source":{"system":"sec-edgar","filing":"0000950170-24-099872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099872/ownership.xml","form_type":"4"}},{"id":1427780,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-08-21T01:14:04.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":6.12,"value":3060.0,"ownership":{"direct":true},"balance_after":565543,"source":{"system":"sec-edgar","filing":"0000950170-24-099351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099351/ownership.xml","form_type":"4"}},{"id":1427779,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-08-21T01:14:04.000Z","date":"2024-08-19","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":6.31,"value":3155.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions on August 19, 2024, at prices ranging from $6.29 to $6.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":565043,"source":{"system":"sec-edgar","filing":"0000950170-24-099351","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024099351/ownership.xml","form_type":"4"}},{"id":1469591,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2024-06-25T23:00:04.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":6925,"price":7.22,"value":49998.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":351527,"source":{"system":"sec-edgar","filing":"0000950170-24-077496","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024077496/ownership.xml","form_type":"4"}},{"id":1469590,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-06-25T23:00:03.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":17854,"price":7.22,"value":128905.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":182146,"source":{"system":"sec-edgar","filing":"0000950170-24-077497","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024077497/ownership.xml","form_type":"4"}},{"id":1469589,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-06-25T23:00:03.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":15659,"price":7.22,"value":113057.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":564543,"source":{"system":"sec-edgar","filing":"0000950170-24-077495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024077495/ownership.xml","form_type":"4"}},{"id":1482188,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:21:49.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072473/ownership.xml","form_type":"4"}},{"id":1482187,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":19062,"kind":"person","name":"GRYSKA DAVID W","position":1,"cik":"0001202335","reported_name":"GRYSKA DAVID W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:17:29.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072468/ownership.xml","form_type":"4"}},{"id":1482186,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38199,"kind":"person","name":"CRYSTAL ROGER","position":1,"cik":"0001656633","reported_name":"CRYSTAL ROGER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:13:58.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072454/ownership.xml","form_type":"4"}},{"id":1482185,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:10:00.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072441/ownership.xml","form_type":"4"}},{"id":1482184,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38197,"kind":"person","name":"Krebs Andreas","position":1,"cik":"0001438946","reported_name":"Krebs Andreas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:06:38.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072427/ownership.xml","form_type":"4"}},{"id":1560692,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":92658,"kind":"person","name":"Greenway Schond L.","position":1,"cik":"0001848205","reported_name":"Greenway Schond L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-03-26T21:16:36.000Z","date":"2024-03-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":5560,"price":9.78,"value":54376.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares withheld to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, as permitted by the Issuer's Performance and Restricted Share Unit Plan."}],"balance_after":211057,"source":{"system":"sec-edgar","filing":"0000950170-24-036578","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024036578/ownership.xml","form_type":"4"}},{"id":1560691,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2024-03-26T21:15:10.000Z","date":"2024-03-25","kind":"sale","planned":true,"acquired":false,"shares":6578,"price":9.5,"value":62491.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2024 at prices ranging from $9.37 to $9.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":358452,"source":{"system":"sec-edgar","filing":"0000950170-24-036573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024036573/ownership.xml","form_type":"4"}},{"id":1560690,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-03-26T21:15:08.000Z","date":"2024-03-25","kind":"sale","planned":true,"acquired":false,"shares":16519,"price":9.5,"value":156930.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2024 at prices ranging from $9.37 to $9.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":580202,"source":{"system":"sec-edgar","filing":"0000950170-24-036572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024036572/ownership.xml","form_type":"4"}},{"id":1610175,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":88070,"kind":"person","name":"Halperin Wernli Miri","position":1,"cik":"0001897615","reported_name":"Wernli Miri Halperin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:50.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with  the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-24-023205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023205/ownership.xml","form_type":"4"}},{"id":1610174,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":92658,"kind":"person","name":"Greenway Schond L.","position":1,"cik":"0001848205","reported_name":"Greenway Schond L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:44.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-24-023204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023204/ownership.xml","form_type":"4"}},{"id":1610173,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:38.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-24-023201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023201/ownership.xml","form_type":"4"}},{"id":1610172,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:33.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-24-023200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023200/ownership.xml","form_type":"4"}},{"id":1610171,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":81525,"kind":"person","name":"Liao Carrie","position":1,"cik":"0001899817","reported_name":"Liao Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:21.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-023203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023203/ownership.xml","form_type":"4"}},{"id":1610170,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":10322,"kind":"person","name":"Barrow Robert","position":1,"cik":"0001897557","reported_name":"Barrow Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:16.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":400000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-023202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023202/ownership.xml","form_type":"4"}},{"id":1700175,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24157,"kind":"person","name":"Karlin Daniel","position":1,"cik":"0001897618","reported_name":"Karlin Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Shares","published_at":"2023-12-26T21:59:47.000Z","date":"2023-12-26","kind":"sale","planned":false,"acquired":false,"shares":6774,"price":3.63,"value":24589.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2023 at prices ranging from $3.60 to $3.67 US Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":365030,"source":{"system":"sec-edgar","filing":"0000950170-23-073078","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017023073078/ownership.xml","form_type":"4"}}],"next_cursor":"2023-12-26T21:59:47.000000Z,1700175"}